Mablink Bioscience will present the latest technological advances of its ADC platform for highly-loaded & highly hydrophilic ADCs
Mablink Bioscience is looking forward to the 10th edition of the World ADC congress in London, Europe’s longest standing and most comprehensive forum in the ADC field.
Mablink is adopting Agatha’s solution, a global leader in quality and content management solutions for life sciences.
Discover Mablink’s ADC platform and meet our COO Valérie Attuil-Audenis and our CEO Jean-Guillaume Lafay at BioFIT Event on December 10 and 11 in Marseille
Mablink receives the support of the Canceropole CLARA to push forward the development of its ADC platform
Mablink receives the iLab 2019 award in the presence of French Minister of Higher Education, Research and Innovation, Mrs Frédérique Vidal, and Bpifrance, at the innovation awards ceremony in Paris.
Photo by P. Thiessen Mablink is flying high! The French Journal des Entreprises relates in a recent article Mablink’s last fundraisings with the coming of a new investor for 125k€, …
Mablink receives a €380,000 equity investment from TTO PULSALYS to carry out the preclinical proof of concept of its ADC drug candidate MBK-102 in Non-Hodgkin’s Lymphoma.
After having earned the #FrenchTechSeed label in the middle of March, Puls@lys has made an exclusive communication on our Antibody-Drug linker technology as a breakthrough innovation as well as its …
With more than 700 participants last April 4th/5th, the Auvergne-Rhône-Alpes Cancer Research Forum is one of the most federating events. During this event took place the Research2Business (R2B) Oncology Meeting …